PFIZER - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | PFIZER | Market Cap | 21,592 Cr. | Current Price | 4,724 ₹ | High / Low | 5,993 ₹ |
| Stock P/E | 28.4 | Book Value | 841 ₹ | Dividend Yield | 0.74 % | ROCE | 21.6 % |
| ROE | 16.4 % | Face Value | 10.0 ₹ | DMA 50 | 4,863 ₹ | DMA 200 | 4,974 ₹ |
| Chg in FII Hold | 0.11 % | Chg in DII Hold | -0.06 % | PAT Qtr | 182 Cr. | PAT Prev Qtr | 189 Cr. |
| RSI | 44.4 | MACD | -48.2 | Volume | 7,951 | Avg Vol 1Wk | 35,811 |
| Low price | 3,701 ₹ | High price | 5,993 ₹ | PEG Ratio | 17.9 | Debt to equity | 0.01 |
| 52w Index | 44.7 % | Qtr Profit Var | 43.0 % | EPS | 187 ₹ | Industry PE | 27.2 |
📊 Analysis: Pfizer India shows solid fundamentals and is a reasonably good candidate for long-term investment. The company has strong efficiency metrics — ROCE (21.6%) and ROE (16.4%) — above industry averages. EPS is ₹187, and quarterly PAT remains stable at ₹182 Cr. (slightly down from ₹189 Cr.). The P/E ratio of 28.4 is slightly higher than the industry average (27.2), suggesting mild overvaluation. The PEG ratio of 17.9 indicates growth is not fully aligned with valuation. Dividend yield is modest at 0.74%. Debt-to-equity is very low at 0.01, reflecting a strong balance sheet. Technically, the stock is weak, trading below both 50 DMA (₹4,863) and 200 DMA (₹4,974), with RSI at 44.4 and MACD negative (-48.2).
💰 Ideal Entry Price Zone: A good accumulation zone would be ₹4,500–₹4,700, close to recent lows (₹3,701) and below moving averages. Current price (₹4,724) is within this zone, making cautious accumulation possible for long-term investors.
📈 Exit Strategy / Holding Period: For existing holders, Pfizer India can be held for 5–7 years given strong fundamentals, debt-free status, and consistent profitability. Exit strategy should be considered near ₹5,600–₹5,800 if valuations stretch without earnings growth. Long-term holding is viable if profitability continues to improve and dividend payouts remain consistent.
✅ Positive
- Strong ROCE (21.6%) and ROE (16.4%).
- EPS of ₹187 indicates robust profitability.
- Debt-to-equity ratio very low at 0.01.
- Stable quarterly PAT performance.
- FII holdings increased slightly (+0.11%).
⚠️ Limitation
- P/E ratio (28.4) slightly above industry average (27.2).
- PEG ratio of 17.9 suggests valuation risk.
- Dividend yield modest at 0.74%.
- Stock trading below both 50 DMA and 200 DMA.
📉 Company Negative News
- Quarterly PAT declined slightly (₹189 Cr. → ₹182 Cr.).
- DII holdings decreased (-0.06%).
- Weak technical indicators: RSI at 44.4, MACD at -48.2.
📈 Company Positive News
- Strong efficiency metrics and debt-free balance sheet.
- Consistent long-term profitability track record.
- FII holdings increased (+0.11%).
🏭 Industry
- Industry P/E at 27.2, slightly lower than Pfizer’s valuation.
- Pharmaceutical sector benefits from rising healthcare demand and innovation.
- Strong growth potential in generics, vaccines, and specialty drugs.
🔎 Conclusion
Pfizer India is fundamentally strong with high ROE/ROCE, robust EPS, and a debt-free balance sheet. Despite mild overvaluation and weak technicals, it remains a good candidate for long-term investment. Ideal entry zone is ₹4,500–₹4,700. Existing holders should maintain positions for 5–7 years, with exit considered near ₹5,600–₹5,800 if valuations run ahead of earnings recovery.